会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • INDOLETETRALINS HAVING DOPAMINERGIC ACTIVITY
    • 具有多巴胺活性的吲哚美辛
    • WO1994021608A1
    • 1994-09-29
    • PCT/US1994002800
    • 1994-03-21
    • THE UPJOHN COMPANYANDERSSON, Bengt, RonnyCARLSSON, Per, Arvid, EmilHANSSON, Lars, OlovSONESSON, Clas, AkeSTJERNLOF, Nils, PeterSVENSSON, Kjell, Anders, IvanWATERS, Ross, NicholasHAADSMA-SVENSSON, Susanne, R.
    • THE UPJOHN COMPANY
    • C07D209/60
    • C07D209/58C07D209/60C07D307/92C07D307/93C07D409/12C07D491/04
    • A compound of formula (I) and pharmaceutically acceptable salts thereof, where Z is R3 and X and Y form (a), or X is R3 and Y and Z form (a), (b) or (c); R1 and R2 are independently hydrogen, C1-6 alkyl, C3-7 cycloalkyl, -CH2-C3-7 cycloalkyl, phenyl (optionally substituted with halogen or C1-6 alkyl), -thiophenyl (optionally substituted with halogen or C1-6 alkyl), or C1-6 alkyl phenyl; R3 are independently hydrogen, halogen, -O-C1-6 alkyl or C1-6 alkyl; R4 is a valence bond, CH2 or oxygen; R5 and R6 are independently hydrogen, sulfur, -S-C1-6 alkyl, halogen, CON(R3)2, -COCF3, -CO-C1-6 alkyl, -CO phenyl, oxygen, -CHO, CN except that when Y and Z form (b), R1 and R2 are hydrogen or a C1-6 alkyl and R3 is hydrogen, then at least one of R5 and R6 must be other than hydrogen. These compounds and derivatives thereof exhibit dopamine-receptor stimulating activity in mammals which are useful for treating hyperprolactinemia, galactorrhea, amenorrhea, impotence, Parkinsonism, diabetes, acromegaly, hypertension and other central nervous system disorders which respond to dopamine-receptor stimulation.
    • 其中Z是R3,X和Y形成(a),或X是R3和Y和Z形式(a),(b)或(c)的式(I)化合物及其药学上可接受的盐。 R 1和R 2独立地是氢,C 1-6烷基,C 3-7环烷基,-CH 2 -C 3-7环烷基,苯基(任选被卤素或C 1-6烷基取代) - 噻吩基(任选地被卤素或C 1-6烷基 )或C 1-6烷基苯基; R 3独立地是氢,卤素,-O-C 1-6烷基或C 1-6烷基; R4是价键,CH2或氧; R 5和R 6独立地是氢,硫,-S-C 1-6烷基,卤素,CON(R 3)2,-COCF 3,-CO-C 1-6烷基,-CO苯基,氧,-CHO, 和Z形式(b)中,R 1和R 2是氢或C 1-6烷基,R 3是氢,则R 5和R 6中的至少一个必须不是氢。 这些化合物及其衍生物在哺乳动物中表现出多巴胺受体刺激活性,其可用于治疗响应于多巴胺受体刺激的高催乳素血症,溢乳,闭经,阳ence,帕金森综合征,糖尿病,肢端肥大症,高血压和其他中枢神经系统疾病。
    • 6. 发明申请
    • NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES
    • 新的中央行动取代的苯甲酰氯
    • WO1992018475A2
    • 1992-10-29
    • PCT/US1992002227
    • 1992-03-26
    • THE UPJOHN COMPANYSVENSSON, Kjell, Anders, IvanWIKSTRÖM, Håkan, VilhemCARLSSON, Per, Arvid, EmilBOIJE, Anna, Maria, PersdotterWATERS, Ross, NicholasSONESSON, Clas, AkeSTJERULOF, Nils, PeterANDERSSON, Bengt, RonnyHANSSON, Lars, Olor
    • THE UPJOHN COMPANY
    • C07D0
    • C07D207/08C07D207/09C07D211/14C07D211/18C07D211/22C07D211/24C07D211/28C07D211/34C07D211/76C07D223/04C07D409/06C07D409/10C07D455/02C07D487/04
    • A compound of formula (I), or a pharmaceutically acceptable salt thereof wherein n is 0-3; R and R are independently H (provided only one is H at the same time), -OH (provided R is other than hydrogen), CN, CH2CN, 2- or 4-CF3, CH2CF3, CH2CHF2, CH=CF2, (CH2)2CF3, ethenyl, 2-propenyl, OSO2CH3, OSO2CF3, SSO2CF3, COR , COOR , CON(R )2, SOxCH3 (where, x is 0-2), SOxCF3, O(CH2)xCF3, SO2N(R )2, CH=NOR , COCOOR , COCOON(R )2, C1-8 alkyls, C3-8 cycloalkyls, CH2OR , CH2(R )2, NR SO2CF3, NO2, halogen, a phenyl at positions 2, 3 or 4, thienyl, furyl, pyrrole, oxazole, thiazole, N-pyrroline, triazole, tetrazole or pyridine; R is hydrogen, CF3, CH2CF3, C1-C8 alkyl, C3-C8 cycloalkyl, C4-C9 cycloalkyl-methyl, C2-C8 alkenyl, C2-C8 alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, -(CH2)m-R (where m is 1-8), CH2SCH3 or a C4-C8 alkyl bonded to said nitrogen and one of its adjacent carbon atoms inclusive to form a cyclic structure; R is independently hydrogen, CF3, CH2CF3, C1-C8 alkyl, C3-C8 cycloalkyl, C4-C9 cycloalkyl-methyl, C2-C8 alkenyl, C2-C8 alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, -(CH2)m-R where m is 1-8; R is phenyl, phenyl (substituted with a CN, CF3, CH2CF3, C1-C8 alkyl, C3-C8 cycloalkyl, C4-C9 cycloalkyl-methyl, C2-C8 alkenyl, C2-C8 alkynyl), 2-thiophenyl, 3-thiophenyl, -NR CONR R , or -CONR R ; R and R are independently hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, C4-C9 cycloalkylmethyl, C2-C8 alkenyl or C2-C8 alkynyl; and with the proviso that when R is 2-CN or 4-CN, R is H, R is n-Pr and n is 1 or 3 then such compound is a pure enantiomer. The formula (I) compounds possess selective pharmacological properties and are useful in treating central nervous system disorders related to dopamine receptor activity including depression symptoms, geriatric disorders in the improvement of mental and motor functions, schizophrenia, narcolepsy, MBD, obesitas, and disturbances of sexual functions and impotence.
    • 式(I)化合物或其药学上可接受的盐,其中n为0-3; R 1和R 2独立地是H(同时只有一个是H),-OH(提供的R 4不是氢),CN,CH 2 CN,2-或4- CF 3,CH 2 CF 3 ,CH 2 CF 2,(CH 2)2 CF 3,乙烯基,2-丙烯基,OSO 2 CH 3,OSO 2 CF 3,SSO 2 CF 3,COR 4,COOR 4,CON(R 4)2,SO x CH 3(其中,x为0 -2),SO x CF 3,O(CH 2)x CF 3,SO 2 N(R 4)2,CH = NOR 4,COCOOR 4,COCOON(R 4)2,C 1-8烷基, 环烷基,CH 2 OR 4,CH 2(R 4)2,NR 4 SO 2 CF 3,NO 2,卤素,2,3或4位的苯基,噻吩基,呋喃基,吡咯,恶唑,噻唑,N-吡咯啉, 三唑,四唑或吡啶; R 3是氢,CF 3,CH 2 CF 3,C 1 -C 8烷基,C 3 -C 8环烷基,C 4 -C 9环烷基 - 甲基,C 2 -C 8烯基,C 2 -C 8炔基,3,3,3-三氟丙基, (CH 2)m R 5(其中m为1-8),CH 2 SCH 3或与所述氮键合的C 4 -C 8烷基及其相邻碳原子之一,以形成环状结构; R 4独立地是氢,CF 3,CH 2 CF 3,C 1 -C 8烷基,C 3 -C 8环烷基,C 4 -C 9环烷基 - 甲基,C 2 -C 8烯基,C 2 -C 8炔基,3,3,3-三氟丙基, ,4-三氟丁基, - (CH 2)m R 5,其中m为1-8; R 5是苯基(被CN,CF 3,CH 2 CF 3,C 1 -C 8烷基,C 3 -C 8环烷基,C 4 -C 9环烷基 - 甲基,C 2 -C 8烯基,C 2 -C 8炔基),2-噻吩基, 3-噻吩基,-NR 6 CONR 6 R 7或-CONR 6 R 7; R 6和R 7独立地是氢,C 1 -C 8烷基,C 3 -C 8环烷基,C 4 -C 9环烷基甲基,C 2 -C 8烯基或C 2 -C 8炔基; 并且条件是当R 1为2-CN或4-CN时,R 2为H,R 3为n-Pr,n为1或3,则该化合物为纯对映异构体。 式(I)化合物具有选择性药理学性质,并且可用于治疗与多巴胺受体活性相关的中枢神经系统疾病,包括抑郁症状,改善精神和运动功能的老年疾病,精神分裂症,发作性睡病,脑血管疾病,肥胖症和干扰 性功能和阳。。